Skip to main content
Publications
Hansford HJ, Cashin AG, Jones MD, Swanson SA, Islam N, Douglas SRG, Rizzo RRN, Devonshire JJ, Williams SA, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X , Golub RM, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sterne JAC, Sharp MK, Stuart EA, Hernan MA, Lee H, McAuley JH. Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review . JAMA Netw Open. 2023 Sep 5;6(9):e2336023. doi: 10.1001/jamanetworkopen.2023.36023
Armstrong MA, Raine-Bennett T, Reed SD, Gatz J, Getahun D, Schoendorf J, Postlethwaite D, Fassett MJ, Peipert JF, Saltus CW , Merchant M, Alabaster A, Zhou X , Ichikawa L, Shi JM, Chiu VY, Xie F, Hunter S, Wang J , Ritchey ME, Chillemi G, Im TM, Takhar HS, Pisa F, Asiimwe A, Anthony MS . Association of the timing of postpartum intrauterine device insertion and breastfeeding with risks of intrauterine device expulsion . JAMA Netw Open. 2022 Feb 28;5(2):e2148474. doi: 10.1001/jamanetworkopen.2021.48474
Phiri K, Hallas J, Linder M, Margulia A , Suehs B, Arana A , Bahmanyar S, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S , Sahlertz Kristiansen N, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder . Poster presented at the American Urological Association 2020 Conference (Conference cancelled); May 2020. Washington, DC. [abstract] J Urol. 2020 Apr; 203(Supplement 4):e910-1. doi: 10.1097/JU.0000000000000931.010
Arana A , Margulis AV , McQuay LJ, Ziemiecki R , Bartsch JL , Rothman KJ , Franks B, D Silva M, Appenteng K, Varas-Lorenzo C, Perez-Gutthann S . Variation in cardiovascular risk related to individual antimuscarinic drugs used to treat overactive bladder: a cohort study in the UK . Pharmacotherapy. 2018 Jun;38(6):628-37. doi: 10.1002/phar.2121.
Kaye JA, Castellsague J, Bui CL , Calingaert B , McQuay LJ, Riera-Guardia N , Saltus CW , Quinlan S, Holick CN, Wahl PM, Suzart K, Rothman KJ , Wallander M-A, Perez-Gutthann S . Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study . Pharmacotherapy. 2014 Apr;34(4):336-49. doi: 10.1002/phar.1367